Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.

Johnston TH, Geva M, Steiner L, Orbach A, Papapetropoulos S, Savola JM, Reynolds IJ, Ravenscroft P, Hill M, Fox SH, Brotchie JM, Laufer R, Hayden MR.

Mov Disord. 2018 Dec 21. doi: 10.1002/mds.27565. [Epub ahead of print]

PMID:
30575996
2.

DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.

Johnston TH, Versi E, Howson PA, Ravenscroft P, Fox SH, Hill MP, Reidenberg BE, Corey R, Brotchie JM.

Neuropharmacology. 2018 Mar 15;131:116-127. doi: 10.1016/j.neuropharm.2017.11.046. Epub 2017 Nov 29.

PMID:
29197517
3.

RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease.

Ko WK, Martin-Negrier ML, Bezard E, Crossman AR, Ravenscroft P.

Neurobiol Dis. 2014 Oct;70:138-48. doi: 10.1016/j.nbd.2014.06.013. Epub 2014 Jun 24.

PMID:
24969021
4.

Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit.

Eskow Jaunarajs KL, Standaert DG, Viegas TX, Bentley MD, Fang Z, Dizman B, Yoon K, Weimer R, Ravenscroft P, Johnston TH, Hill MP, Brotchie JM, Moreadith RW.

Mov Disord. 2013 Oct;28(12):1675-82. doi: 10.1002/mds.25625. Epub 2013 Sep 3.

5.

Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys.

Fernagut PO, Li Q, Dovero S, Chan P, Wu T, Ravenscroft P, Hill M, Chen Z, Bezard E.

PLoS One. 2010 Nov 22;5(11):e14053. doi: 10.1371/journal.pone.0014053.

6.

Neuroanatomical study of the A11 diencephalospinal pathway in the non-human primate.

Barraud Q, Obeid I, Aubert I, Barrière G, Contamin H, McGuire S, Ravenscroft P, Porras G, Tison F, Bezard E, Ghorayeb I.

PLoS One. 2010 Oct 13;5(10):e13306. doi: 10.1371/journal.pone.0013306.

7.

Migration and differentiation of human mesenchymal stem cells in the normal rat brain.

Li JM, Zhu H, Lu S, Liu Y, Li Q, Ravenscroft P, Xu YF, Huang L, Ma CM, Bezard E, Zhao RC, Wang RZ, Qin C.

Neurol Res. 2011 Jan;33(1):84-92. doi: 10.1179/016164110X12670144737819. Epub 2010 May 19.

PMID:
20487599
8.

Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate.

Silverdale MA, Kobylecki C, Hallett PJ, Li Q, Dunah AW, Ravenscroft P, Bezard E, Brotchie JM.

Synapse. 2010 Feb;64(2):177-80. doi: 10.1002/syn.20739. No abstract available.

PMID:
19852073
9.

Striatal histone modifications in models of levodopa-induced dyskinesia.

Nicholas AP, Lubin FD, Hallett PJ, Vattem P, Ravenscroft P, Bezard E, Zhou S, Fox SH, Brotchie JM, Sweatt JD, Standaert DG.

J Neurochem. 2008 Jul;106(1):486-94. doi: 10.1111/j.1471-4159.2008.05417.x. Epub 2008 Jul 1.

10.

Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson's disease.

Scheller D, Stichel-Gunkel C, Lübbert H, Porras G, Ravenscroft P, Hill M, Bezard E.

Neurosci Lett. 2008 Feb 13;432(1):30-4. Epub 2007 Dec 8.

PMID:
18162314
11.

Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease.

Scheller D, Chan P, Li Q, Wu T, Zhang R, Guan L, Ravenscroft P, Guigoni C, Crossman AR, Hill M, Bezard E.

Exp Neurol. 2007 Feb;203(2):415-22. Epub 2006 Oct 12.

PMID:
17045989
12.

Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors.

Hill MP, Ravenscroft P, McGuire SG, Brotchie JM, Crossman AR, Rochat C, Millan MJ.

Mov Disord. 2006 Dec;21(12):2090-5.

PMID:
16991143
13.

Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic nonhuman primates: a call for a reappraisal of the functional organization of the basal ganglia.

Nadjar A, Brotchie JM, Guigoni C, Li Q, Zhou SB, Wang GJ, Ravenscroft P, Georges F, Crossman AR, Bezard E.

J Neurosci. 2006 Aug 23;26(34):8653-61.

14.

Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine.

Meissner W, Ravenscroft P, Reese R, Harnack D, Morgenstern R, Kupsch A, Klitgaard H, Bioulac B, Gross CE, Bezard E, Boraud T.

Neurobiol Dis. 2006 Jun;22(3):586-98. Epub 2006 Mar 10.

PMID:
16531050
15.

Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.

Hallett PJ, Dunah AW, Ravenscroft P, Zhou S, Bezard E, Crossman AR, Brotchie JM, Standaert DG.

Neuropharmacology. 2005 Mar;48(4):503-16.

PMID:
15755478
17.

Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate.

Silverdale MA, Nicholson SL, Ravenscroft P, Crossman AR, Millan MJ, Brotchie JM.

Exp Neurol. 2004 Jul;188(1):128-38.

PMID:
15191809
18.

Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.

Hill MP, Ravenscroft P, Bezard E, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H.

J Pharmacol Exp Ther. 2004 Jul;310(1):386-94. Epub 2004 Mar 5.

PMID:
15004218
19.
20.

Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice.

Gross CE, Ravenscroft P, Dovero S, Jaber M, Bioulac B, Bezard E.

J Neurochem. 2003 Mar;84(6):1246-55.

Supplemental Content

Loading ...
Support Center